Page last updated: 2024-12-10

3'-o-(n-methylanthraniloyl)adenosine 5'-diphosphate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3'-O-(N-methylanthraniloyl)adenosine 5'-diphosphate : A purine ribonucleoside 5'-diphosphate that is ADP substituted at position 3' by an N-methylanthraniloyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID2826726
CHEMBL ID399755
CHEBI ID71336
MeSH IDM0217430

Synonyms (16)

Synonym
3'-o-(n-methylanthraniloyl)-adp
adenosine, 3'-[2-(methylamino)benzoate] 5'-(trihydrogen diphosphate)
85287-55-4
adenosine 5'-(trihydrogen diphosphate), 3'-(2-(methylamino)benzoate)
adenosine 5'-(trihydrogen diphosphate), 3'-[2-(methylamino)benzoate] (9ci)
3'-o-(n-methylanthraniloyl)adenosine 5'-diphosphate
CHEMBL399755
chebi:71336 ,
adenosine 5'-(trihydrogen diphosphate) 3'-(2-(methylamino)benzoate)
3'-o-[2-(methylamino)benzoyl]adenosine 5'-(trihydrogen diphosphate)
DTXSID10234490
Q27139521
3'-o-(n-methylanthraniloyl)adenosine-5'-diphosphate
[(2~{r},3~{s},4~{r},5~{r})-5-(6-aminopurin-9-yl)-4-oxidanyl-2-[[oxidanyl(phosphonooxy)phosphoryl]oxymethyl]oxolan-3-yl] 2-(methylamino)benzoate
tg8 ,
(2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-4-hydroxy-2-(((hydroxy(phosphonooxy)phosphoryl)oxy)methyl)tetrahydrofuran-3-yl 2-(methylamino)benzoate
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
purine ribonucleoside 5'-diphosphate
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID310935Inhibition of adenylyl cyclase2007Bioorganic & medicinal chemistry, Apr-15, Volume: 15, Issue:8
A conformational transition in the adenylyl cyclase catalytic site yields different binding modes for ribosyl-modified and unmodified nucleotide inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (48)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's13 (27.08)18.2507
2000's33 (68.75)29.6817
2010's2 (4.17)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.41

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.41 (24.57)
Research Supply Index3.89 (2.92)
Research Growth Index4.30 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.41)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other48 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]